Title page

Title: The time is ripe to harmonize global acute febrile illness etiologic investigations

Running title: Harmonization of acute febrile illness investigations methods

Article category: Letter

Author names & institutional affiliations: José Moreira[1,2], B. Leticia Fernando-Carballo[3],

Camille Escadafal[3], Sabine Dittrich[3,4], Patrícia Brasil[1], André M Siqueira[1]

Affiliations:

1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de

Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

2. Instituto Nacional de Cardiologia, Departamento de Ensino e Pesquisa, Rio de Janeiro,

Brazil

3. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Corresponding author: José Moreira MD Ph.D; e-mail: jose.moreira@ini.fiocruz.br;

telephone number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris

Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av.

Brasil, 4365 – Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j_moreira_

Keywords: Antipyretic therapy; Fever; Acute febrile illness; Dipyrone; Methodology

Abstract

Acute febrile illness (AFI) is common for people seeking care globally and represents a spectrum of

infectious and non-infectious etiologies with significant geographical variations. However, AFI

research follows a heterogeneous methodology and reporting, making it challenging for individual

fever studies interpretation and comparison and thus generating evidence-based decisions. Herein,

we aim to conduct a pilot study investigating the impact of considering different case definitions of

fever as inclusion criteria among febrile patients attending two Emergency Departments (ED) in Rio

de Janeiro, Brazil, from October 28, 2018, to March 29, 2019. Secondarily, we explored the impact of

the recent use of antipyretics in measured temperature at the arrival of the EDs. A prospective study

was conducted, and we screened all consecutive non-severe patients who presented to the EDs. The

inclusion criterion was the self-report of fever regardless of the temperature measured. A logistic

regression model was built to investigate the factors associated with a febrile presentation at the

arrival of EDs. We triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a history of fever, of

whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <37.5°C, $\geq$ 37.5 °C, and no

temperature measurement registered at arrival, respectively. 198/374 (53%) had a suspicion of

infection, and the site of infection varied according to the height of temperate at presentation. The

antibiotic prescription was more likely in those who had a temperature $\geq$ 37.5 °C compared to those

with a temperature <37.5°C [crude OR: 2 (95% 1.1-3.5)]. 249/374 (66.6%) subjects reported self-

administering an antipyretic within 2h [IQR 2-6] before EDs. Recent antipyretic uptake did not

influence the measured temperature at presentation. In conclusion, we suggest harmonizing the

case definition of fever in AFI research for a history of fever regardless of temperature cut-off would

enable a complete picture of the different clinical fever phenotypes, thus improving our

understanding of the global burden of febrile illness.

Text

Acute febrile illness (AFI) is a common reason for people seeking care and represents a range

of infectious and non-infectious diseases, with wide variation by region of the globe [1]. AFI

investigations aim to inform national and subregional treatment guidelines about empirical

and pathogen-specific treatment algorithms to prioritize interventions and funding. Several

AFI investigations have been conducted primarily in Southeast Asia, with few global

initiatives in resource-constrained countries [2]. However, there is no standardized approach

to conducting such studies, limiting the interpretation and comparability of study findings.

We were involved in a multinational project around fever host-biomarkers [3] and aimed to

conduct a pilot study to inform the best criteria for our study site selection. We hypothesized

that adopting a subjective or self-reported fever assessment as part of our inclusion criteria

would increase the sensibility threshold for a broad array of febrile clinical phenotypes rather

than specifying a cut-off value for fever. Another hypothesis was that the recent antipyretic

intake would lower body temperature at the arrival of the Emergency Departments (EDs).

Here, we did a cross-sectional, study of patients presenting to two urban EDs (Unidade de

Pronto Atendimento Manguinhos & Unidade de Pronto Atendimento Rocha Miranda) in Rio

de Janeiro, Brazil, between October 28, 2018, and March 29, 2019. The study was conducted

following the Declaration of Helsinki and the Brazilian National Ethics Research Committee

and was approved in August 2018 (IRB approval no:70984617.9.0000.5262). We screened

all consecutive non-severe patients who presented to the EDs over the study period and

included those who reported fever ≤ 7 days regardless of temperature measured at the EDs.

Research assistants collected prospectively detailed information and interviewed participants

or the primary caregivers to obtain data about the demographics, main chief complaint, vital

signs, history of fever, peak measured temperature before arrival at the EDs (temperature

maximum), the measured temperature at the EDs, home administration of antipyretics,

type/dose/timing of last administration, and tests performed at the EDs. Discharge diagnosis

and treatment received after discharge was retrospectively collected by reviewing electronic

medical records. The attending physician proposed the discharge diagnosis (not involved in

the study), and its appropriateness was not re-evaluated. We used the following definitions:

fever was subjectively identified by the participant at arrival at the EDs; antipyretics are

mostly nonprescription drugs that act on the fever physiologic pathway, inhibiting the release

of pyrogenic cytokines and lowering the core body temperature, and those were self-

administered by the participants before seeking emergency care; adults those aged ≥ 18 years

at recruitment, and non-severe AFI was an illness that was codified as blue or green

according to the Manchester Triage System at EDs, which does not require hospital

admission. We measured the axillary temperature at triage and estimated the magnitude of

defervescence, considering the highest measured self-reported temperature before EDs arrival

(Tmax). Suspected infection was defined as the initiation of any antimicrobial after an EDs

visit. We built a logistic regression model to investigate the factors associated with febrile

presentation (i.e., temperature ≥ 37.5 °C) among patients attending the study sites. The

primary outcome was to investigate the impact of considering different definitions of fever as

inclusion criteria among febrile patients attending EDs.

During the study period, we triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a

history of fever at arrival at the ED, corresponding to a cumulative incidence of fever at EDs

of 24 per 100 triaged patients over the five months. These 374 febrile patients constitute our

study population, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <

37.5 °C, ≥ 37.5 °C, and no temperature measurement registered at arrival, respectively. The

mean age was 30.6 [range: 0-84] years, adults (82.5%) and females (54.8%) predominated

(Table). The median peak measured temperature before arrival at the ED was 38.8°C (38.0-

39.0), and the median duration of fever was 1 [1-3] days.

Hundred ninety-eight febrile patients had a suspicion of infection, with upper respiratory tract

infection (42.4%) followed by undifferentiated febrile illness (15.7%) and urinary tract

infection (14.6%) were the primary febrile syndromes (Supplementary Figure 1). The most

commonly prescribed antibiotic classes were beta-lactams (73/131, 55.7%), quinolones

(23/131, 17.5%) and macrolides (16/131,12.2%). Patients who had temperature ≥ 37.5 °C at

presentation were more likely to be diagnosed with an infection [76 (66%) *vs*. 116 (47%),

crude OR: 2.2 (95% 1.4-3.5) and were prescribed antibiotic most frequently compared to

those with temperature < 37.5 °C [54 (65%) *vs*. 75 (48%), crude OR: 2 (95% 1.1-3.5)].

The site of infection varied by the height of temperature mensurated at arrival at EDs

(*p*<0.001). Patients who had a temperature < 37.5 °C at presentation were more likely to be

diagnosed with upper respiratory (31.6%) and urinary infections (15.4%) (Supplementary

Figure 3). The most frequently etiology diagnostics recorded in those with temperature <

37.5 °C at presentation were acute pharyngitis (20/248, 8%), followed by community-

acquired gastroenteritis (19/248, 7.6%), uncomplicated urinary tract infection (16/248,

6.4%), cutaneous abscess (14/248, 5.6%), and community-acquired pneumonia (9/248,

3.6%).

In total, 249/374 (66.6% (95% 61.5-71.3)]) subjects reported self-administering an

antipyretic at home within a median of 2h [IQR 2-6] before EDs admission (24.1% of the

febrile subjects did not recall prior antipyretics intake). Dipyrone (72.2%) was the antipyretic

drug most frequently administered, followed by acetaminophen (14.3%) and ibuprofen

(6.3%). Most antipyretic takers consumed one class (85.9%), and the median number of

doses taken was 2 [IQR 1-3]. Of these 249 subjects, 167/249 (67%) reported the last dose

administered at a mean of 2 [2-5] hours before hospital presentation. Subjects who were

treated with an antipyretic drug before arrival did not differ from untreated ones regarding the

temperature at arrival at the ED visit (37 ± 0.99 *vs*. 36.8 ± 0.86, *p* = 0.20) or the documented

Tmax before the ED arrival (38.8 ± 0.79 *vs*. 38.4 ± 0.60, *p* = 0.29). In the model adjusted for

other confounder variates (gender, age, heart rate, number of antipyretics administered, time-

lapse since the last dose of antipyretics administered, time of fever onset, and prior antibiotic

intake), the variable that was independently associated with a febrile presentation was the

heart rate (adjusted OR: 1.035 [95% CI:1.005-1.067].

Our study suggests that considering a subjective/self-reported fever as an inclusion criterion

rather than a specific fever cut-off value (i.e., ≥ 37.5 °C) for AFI etiologic investigation

results in a more inclusive study population and account for the diversity of clinical fever

phenotypes that are usually seen in clinical practice. Specifically, sixty-six percent of our

cohort would not have been included if we restricted our inclusion criteria to a specific febrile

cut-off, potentially impacting study recruiting and patient characterization. Almost half

(47.8%) of febrile participants with temperature < 37.5 °C at presentation were prescribed at

least one antibiotic, and their infections were mainly upper respiratory, justifying their

inclusion in AFI studies. Next, our findings suggest that the ubiquitous administration of

antipyretics (66.6%) observed in our setting did not influence the febrile presentation of

patients attending the EDs evaluated.

We concur with others [2, 4] and argue that there is an urgent need to standardize AFI study

protocols to make sure that we can compare results from different studies and pool their

results to develop national, regional, or global burden of fever estimates. Such consensus in

AFI research would allow better comparisons, translate evidence to practice, and inform

treatment policy. A harmonized definition of fever would enable a more robust and consistent

capture of different clinical phenotypes, including those conditions where overt fever occurs

inconsistently, such as upper respiratory infections and uncomplicated urinary infections.

Others [2] have suggested an adapted STROBE checklist for conducting and reporting AFI

research.

In conclusion, we suggest harmonizing the case definition of fever in AFI research for a

history of fever regardless of temperature cut-off would enable a complete picture of the

different clinical fever phenotypes, thus improving our understanding of the global burden of

febrile illness.

Author contributions

JM: writing original draft, visualization, conceptualization. BC: Review and editing. CE:

Review and editing. SD: review, editing. PB: conceptualization, writing, editing, supervision.

AS: conceptualization, writing, editing, supervision

Funding

The Biomarker for Fever-Diagnostic (BFF-Dx) study was funded by the Dutch, Australian

and UK governments.

Transparency declaration

The authors have no conflict of interest to declare.

References

1. Moreira J, Bressan CS, Brasil P, Siqueira AM. Epidemiology of acute febrile illness

in Latin America. Clin Microbiol Infect. 2018; 24(8):827-835.

2. Rhee C, Kharod GA, Schaad N et al. Global knowledge gaps in acute febrile illness

etiologic investigations: a scoping review. PLoS Negl Trop Dis. 2019; 13(11):

e0007792.

3. Escadafal C, Geis S, Siqueira AM, et al. Bacterial versus non-bacterial infections: a

methodology to support use-case-driven product development of diagnostics. *BMJ*

Glob Health. 2020; 5(10)e:003141.2.

4. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and

without evidence-based treatments. BMC Med. 2010; 18(1):287.

Supplementary Tables

Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile

patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March

2019

Supplementary Figures

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients

attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of

infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,

October 2018-March 2019

Supplementary Figure 3. Foci of infection according to the height of temperature

mensurated at arrival in febrile patients attending Emergency departments in Rio de

Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated

at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,

October 2018-March 2019

199 Table. Baseline characteristics according to the height of temperature mensurated at arrival
200 in febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018-
201 March 2019
202

	Total febrile population N= 374	History of fever but temperature < 37.5 °C N= 248	History of fever and temperature ≥ 37.5 °C N= 115	*p*-value
Characteristics				
Demographics				
Age (years), mean (±SD)	31 (16)	32 (15)	28 (16)	**0.02**
Male, n- (%)	169 (45.2)	103 (41.5)	62 (53.9)	**0.02**
Temp at arrival, (°C), mean (±SD)	37.08 (0.9)	36.55 (0.5)	38.24 (0.6)	**<0.01**
Tmax (°C), mean (±SD)	38.7 (0.7)	38.7 (0.69)	38.95 (0.9)	0.12
Days of fever, mean (±SD)	1.58 (17.4)	1.45 (21.2)	1.80 (3.2)	0.86
Degree of defervescence from Tmax, mean (±SD)	1.70 (1.13)	2.16 (0.86)	0.78 (1.04)	**<0.01**
Diagnosis and management				
Diagnostic testing – n (%)	76 (30.2)	42 (26.1)	32 (38.1)	0.05
Recent antibiotic use – n (%)	21 (12.2)	11 (9.6)	10 (18.9)	0.09
Recent antipyretic use – n (%)	249 (66.6)	169 (87.1)	76 (90.5)	0.42
Antibiotic prescription – n (%)	131 (53.0)	75 (47.8)	54 (65.1)	**0.01**

203 SD means standard deviation; Tmax higher temperature self-recorded at home before
204 emergency department visit
205

Key messages

• Fever is a common reason to seek care in patients attending urban Emergency
Departments in Rio de Janeiro, Brazil

• Suspicion of infection is the underlying cause of fever in 53% of the febrile subjects,
and the respiratory source is the main focus of infection

• The use of antipyretics among febrile patients attending urban Emergency
Departments in Rio de Janeiro is ubiquitous, and dipyrone is the antipyretic of choice
in our population. However, such use did not influence febrile presentation in
Emergency Departments

• Our findings are essential for designing fever etiology and question the value of
adopting specific temperature criteria for fever at enrollment, as in many fever
studies. We believe that a history of fever as part of inclusion criteria is a good
surrogate of unwellness and might be incorporated systematically in future fever
studies.

Appendix Table of Contents

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplementary Tables

- Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figures

- Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

- Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

- Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

- Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients

attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 2. Variability in antibiotic prescription according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Presumed diagnosis by febrile syndrome	Number of presentations n/N (%)	Number of patients receiving an antibiotic prescription n/N (%)
Gastrointestinal		
Gastroenteritis	16/17 (94.11)	7/16 (43.75)
Gastritis	1/17 (5.88)	1/1 (100)
Upper respiratory tract infection		
Acute tonsillitis	34/84 (40.47)	34/34 (100)
Acute pharyngitis	22/84 (26.19)	5/22 (22.72)
Acute sinusitis	8/84 (9.52)	6/8 (75)
Common cold	5/84 (5.95)	0/5 (0)
Other upper respiratory tract infections	15/84 (17.85)	9/15 (60)
Lower respiratory tract infection		
Acute bronchitis and COPD exacerbations	3/17 (17.64)	2/3 (66.66)
Community-acquired pneumonia	9/17 (52.94)	8/9 (88.88)
Influenza	2/17 (11.76)	0/2 (0)
Other lower respiratory tract infections	3/17 (17.64)	3/3 (100)
Skin and soft tissue infection		
Cellulitis and abscesses	14/19 (73.68)	14/14 (100)
Other infection of the skin and soft tissue	4/19 (21.05)	4/4 (100)
Bacterial skin infection	1/19 (5.26)	1/1 (100)
Urinary tract infection		
Uncomplicated cystitis & pyelonephritis	28/29 (96.55)	25/28 (89.28)
Other urinary infection	1/29 (3.44)	1/1 (100)
Acute undifferentiated febrile illness		
Arboviruses	5/30 (16.66)	0/5 (0)
Unspecified febrile illness	6/30 (20)	4/6 (66.66)
Leptospirosis	2/30 (6.66)	2/2 (100)
Unspecified viral infection	15/30 (50)	1/15 (6.66)
Other	1/30 (3.33)	1/1 (100)

COPD stands for chronic obstructive pulmonary disease